Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus placebo after radical resection for high-risk invasive urothelial carcinoma
NL-OMON47449Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC), bladder cancer and upper tract urothelial carcinoma (UTUC) comparing Nivolumab with Placebo (2 arms). Primary endpoints: Disease-free survival in PD-L1 positive tumors and Disease-free survival in all randomized subjects. Started Dec 2016; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancerupper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NL-OMON47449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47449.